Emerging drugs for irritable bowel syndrome

Expert Opinion on Emerging Drugs

Volumn 14, Issue 4, 2009, Pages 673-685

  Shekhar, Chander ^a   Whorwell, Peter J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

5 HT; Benzodiazepine; CCK; Channelopathies; Chloride channel; CRH; Guanylate cyclase; IBS; Neurokinin; Opioid; Probiotics

Indexed keywords

ALOSETRON; ANTIDIARRHEAL AGENT; ASIMADOLINE; ATI 7505; BENZODIAZEPINE DERIVATIVE; BULKING AGENT; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CILANSETRON; CISAPRIDE; CODEINE; DEXLOXIGLUMIDE; DEXTOFISOPAM; GUANILIB; GW 876008; LAXATIVE; LINACLOTIDE; LUBIPROSTONE; MD 110; MORPHINE; OPIATE AGONIST; PLACEBO; PRUCALOPRIDE; PUMOSETRAG; RENZAPRIDE; SEROTONIN 4 AGONIST; SEROTONIN AGONIST; SPASMOLYTIC AGENT; TD 5108; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH CARE NEED; HEART DISEASE; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; NONHUMAN; PAIN; PATHOPHYSIOLOGY; POLYURIA; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

DRUG DESIGN; DRUG INDUSTRY; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; IRRITABLE BOWEL SYNDROME; SEROTONIN; TREATMENT OUTCOME;

EID: 71649091222     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210903222279     Document Type: Review

References (143)

1. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2(6138):653-654
2. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130(5):1480-1491
3. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003;17(5):643-650
4. Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119(3):654-660
5. Smith GD, Steinke DT, Kinnear M, et al. A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode IBS study. Br J Gen Pract 2004;54(504):503-507
6. Akehurst RL, Brazier JE, Mathers N, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002;20(7):455-462
7. Houghton LA, Atkinson W, Whitaker RP, et al. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003;52(5):663-670
8. Houghton LA, Atkinson W, Lockhart C, et al. Sigmoid-colonic motility in health and irritable bowel syndrome: a role for 5-hydroxytryptamine. Neurogastroenterol Motil 2007;19(9):724-731
9. Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998;42(6):845-849
10. Harvey RF, Read AE. Effect of cholecystokinin on colonic motility and symptoms in patients with the irritable-bowel syndrome. Lancet 1973;1(7793):1-3
11. Houghton LA, Jackson NA, Whorwell PJ, Morris J. Do male sex hormones protect from irritable bowel syndrome? Am J Gastroenterol 2000;95(9):2296-2300
12. Houghton LA, Lea R, Jackson N, Whorwell PJ. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 2002;50(4):471-474
13. Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol 2007;42(Suppl 17):41-47
14. Spiller RC. Infection, immune function, and functional gut disorders. Clin Gastroenterol Hepatol 2004;2(6):445-455
15. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128(3):541-551
16. Trimble KC, Farouk R, Pryde A, et al. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 1995;40(8):1607-1613
17. Kwan CL, Diamant NE, Mikula K, Davis KD. Characteristics of rectal perception are altered in irritable bowel syndrome. Pain 2005;113(1-2):160-171
18. McKee DP, Quigley EM. Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 2. Motility of the small bowel, esophagus, stomach, and gall-bladder. Dig Dis Sci 1993;38(10):1773-1782
19. Evans PR, Bak YT, Shuter B, et al. Gastroparesis and small bowel dysmotility in irritable bowel syndrome. Dig Dis Sci 1997;42(10):2087-2093
20. Chey WY, Jin HO, Lee MH, et al. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001;96(5):1499-1506
21. Miller V, Hopkins L, Whorwell PJ. Suicidal ideation in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2004;2(12):1064-1068 (Pubitemid 40037636)
22. Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008;337:a2313
23. Quartero AO, Meineche-Schmidt V, Muris J, et al. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005;18(2):CD003460
24. Schoenfeld P. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work. Gastroenterol Clin North Am 2005;34(2):319-35, viii
25. Lesbros-Pantoflickova D, Michetti P, Fried M, et al. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;20(11-12):1253-1269
26. Bijkerk CJ, Muris JW, Knottnerus JA, et al. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;19(3):245-251
27. Van Outryve M, Milo R, Toussaint J, et al. "Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol 1991;13(1):49-57
28. Schutze K, Brandstatter G, Dragosics B, et al. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol Ther 1997;11(2):387-394
29. Barbey JT, Lazzara R, Zipes DP. Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. J Cardiovasc Pharmacol Ther 2002;7(2):65-76
30. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001;161(14):1733-1740
31. Lembo AJ, Olden KW, Ameen VZ, et al. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol 2004;2(8):675-682
32. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16(11):1877-1888
33. Tack J, Muller-Lissner S, Bytzer P, et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005;54(12):1707-1713
34. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 2007;17(4):CD003960
35. Available from: http://www.fda.gov/cder/drug/infopage/zelnorm/default. htm. [Cited 2007]
36. Available from: http://www.fda.gov/cder/drug/infopage/lotronex/lotronex. htm. [Cited]
37. Available from: http://www.nature.com/nrd/journal/v5/n2/full/nrd1961. html.
38. Available from: http://www.pharmaprojects.com/
39. Available from: http://www.nature.com/nrd/journal/v5/n2/full/nrd1961. html.
40. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007;132(1):397-414
41. Beattie DT, Smith JA. Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn Schmiedebergs Arch Pharmacol 2008;377(3):181-203
42. Available from: http://www.alizyme.com/alizyme/products/renzapride/
43. Briejer MR, Bosmans JP, Van Daele P, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 2001;423(1):71-83
44. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999;44(5):682-686
45. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120(2):354-360
46. Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002;16(7):1347-1356
47. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358(22):2344-2354
48. Tack J, Van Outryve M, Beyens G, et al. Prucalopride (resolor(R)) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58(3):357-365
49. Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. Eur J Pharmacol 2007;554(2-3):98-105
50. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29(3):315-328
51. Dwight E, Moulin AR, Kerstens R, Vandeplassche L. Randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor® ) in patients with opioid-induced constipation. Gastroenterology 2008;134(4):A-92
52. Smith JA, Beattie DT, Marquess D, et al. The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008;378(1):125-137
53. Beattie DT, Armstrong SR, Shaw JP, et al. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008;378(1):139-147
54. Camilleri M, McKinzie S, Sweetser S, et al. Dose-related effects of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity, on gastrointestinal (GI) and colonic transit in healthy volunteers. Neurogastroenterol Motil 2008;20(S 2):6
55. Goldberg MR, Li Y-P, Pitzer K, et al. TD-5108, a selective 5-HT4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation. Gastroenterology 2008;134(4):A-545
56. Goldberg M, Garofalo B, Valmonte A, et al. In patients with chronic constipation, TD-5108, a selective 5-HT4 agonist with high intrinsic activity, relieves straining and bloating, normalizes stool consistency and reduces laxative use. Gastroenterology 2008;134(4):A-547
57. Camilleri M, Vazquez-Roque MI, Burton D, et al. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007;19(1):30-38
58. Coleman NS, Marciani L, Blackshaw E, et al. Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Aliment Pharmacol Ther 2003;18(10):1039-1048
59. Fujita T, Yokota S, Sawada M, et al. Effect of MKC-733, a 5-HT receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study. J Clin Pharm Ther 2005;30(6):611-622
60. Paterson WG, Ford D, Ganguli SC, et al. A novel, oral 5HT3 partial agonist, DDP-733, improves overall response in patients with irritable bowel syndrome and constipation (IBS-C): a randomized, double-blind, placebo-controlled, parallel-group, dose ranging study. Gastroenterology 2008;134(s):A456-7
61. Available from: http://www.clinicaltrials.gov/ct/show/NCT00547469?order= 1.
62. Naliboff BD, Wu SM, Pham Q. Clinical considerations in the treatment of chronic pain with opiates. J Clin Psychol 2006;62(11):1397-1408
63. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182(5A Suppl):11S-8S
64. Rogers M, Cerda JJ. The narcotic bowel syndrome. J Clin Gastroenterol 1989;11(2):132-135
65. Bradesi S, Herman J, Mayer EA. Visceral analgesics: drugs with a great potential in functional disorders? Curr Opin Pharmacol 2008;8(6):697-703
66. Barber A, Bartoszyk GD, Bender HM, et al. A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753. Br J Pharmacol 1994;113(4):1317-1327
67. Schreiber R, Bartoszyk GD, Kunzelmann K. The kappa-opioid receptor agonist asimadoline inhibits epithelial transport in mouse trachea and colon. Eur J Pharmacol 2004;503(1-3):185-190
68. Larsson MH, Bayati A, Lindstrom E, Larsson H. Involvement of kappa-opioid receptors in visceral nociception in mice. Neurogastroenterol Motil 2008;20(10):1157-1164
69. Delvaux M, Beck A, Jacob J, et al. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004;20(2):237-246
70. Szarka LA, Camilleri M, Burton D, et al. Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 2007;5(11):1268-1275
71. Mangel AW, Bornstein JD, Hamm LR, et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008;28(2):239-249
72. Floyd BN, Camilleri M, Busciglio I, et al. Effect of a kappa-opioid agonist, i.v. JNJ-38488502, on sensation of colonic distensions in healthy male volunteers. Neurogastroenterol Motil 2009;21(3):281-290
73. Horvath EJ, Horvath K, Hamori T, et al. Anxiolytic 2,3-benzodiazepines, their specific binding to the basal ganglia. Prog Neurobiol 2000;60(4):309-342
74. Horvath EJ, Palkovits M, Lenkei Z, et al. Autoradiographic localization and quantitative determination of specific binding sites of anxiolytic homophthalazines (formerly called 2,3-benzodiazepines) in the striato-pallido-nigral system of rats. Brain Res Mol Brain Res 1994;22(1-4):211-218
75. Leventer SM, Keogh JC, Raudibaugh K, et al. The potential of dextofisopam for treatment of irritable bowel syndrome and inflammatory bowel disease. Am J Gastroenterol 2004;99(10):S279
76. Leventer SM, Raudibaugh K, Frissora CL, et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008;27(2):197-206
77. Liddle RA. Cholecystokinin cells. Annu Rev Physiol 1997;59:221-242
78. Noble F, Wank SA, Crawley JN, et al. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 1999;51(4):745-781
79. Crawley JN, Corwin RL. Biological actions of cholecystokinin. Peptides 1994;15(4):731-755
80. Kellow JE, Miller LJ, Phillips SF, et al. Sensitivities of human jejunum, ileum, proximal colon, and gallbladder to cholecystokinin octapeptide. Am J Physiol 1987;252(3 Pt 1):G345-56
81. Cremonini F, Camilleri M, McKinzie S, et al. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol 2005;100(3):652-663
82. Meyer BM, Werth BA, Beglinger C, et al. Role of cholecystokinin in regulation of gastrointestinal motor functions. Lancet 1989;2(8653):12-15
83. Rettenbacher M, Reubi JC. Localization and characterization of neuropeptide receptors in human colon. Naunyn Schmiedebergs Arch Pharmacol 2001;364(4):291-304
84. Varga G, Balint A, Burghardt B, D'Amato M. Involvement of endogenous CCK and CCK1 receptors in colonic motor function. Br J Pharmacol 2004;141(8):1275-1284
85. Bonnafous C, Griffin PH, Schneier H. Influence of dexloxiglumide on visceromotor and pain response induced by recta distension in rats. Gastroenterology 2002;122(4):S1
86. Whorwell PJ, D'Amato M, Giacovelli G, et al. A phase III, 6-month, double-blind, placebo-controlled, randomized withdrawal trial of the selective CCK-1 antagonist dexloxiglumide in constipation -predominant IBS: the DARWIN study. Gastroenterology 2008;134(4 Suppl 1):A157
87. Forte LR. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Regul Pept 1999;81(1-3):25-39
88. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation- predominant irritable bowel syndrome. Gastroenterology 2007;133(3):761-768
89. Johnston J, MacDougall J, Lavins B, et al. Linaclotide significantly improved abdominal pain, constipation and global assessments in adults with irritable bowel syndrome with constipation: Results from a Large Twelve-Week, Randomized, Double-Blind, Placebo-Controlled Study. Am J Gastroenterol 2008;103:S460
90. Johnston J, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009;104(1):125-132
91. Lembo AJ, MacDougall JE, Lavins BJ, et al. Linaclotide significantly improved bowel habits and relieved abdominal symptoms in adults with chronic constipation: Data from a Large 4-Week, Randomized, Double-Blind, Placebo-Controlled Study. Gastroenterology 2008;135(1):295
92. Ustinova E, Reza T, Currie M, Pezzone M. Oral Cyclic Guanosine Monophosphate (cGMP) desensitizes colonic afferents in an animal model of experimental colitis. Am J Gastroenterol 2008;103:S187
93. Bueno L, Eutamen H, Gillet M, et al. Effect of oral cyclic GMP on TNBS-induced colitis and visceral hypersensitivity in rats. Am J Gastroenterol 2008;103:S458
94. Busby RW, Bryant AP, Cordero EA, et al. The molecular target of MD-1100 is Guanylate Cyclase C (GC-C), an apical receptor on intestinal epithelial cells. Gastroenterol Clin North Am 2005;128(4 Suppl 2):A464
95. Elena Ustinova AB, Reza T, Currie M, et al. Medicine: oral Cyclic Guanosine Monophosphate (cGMP) desensitizes colonic afferents in an animal model of experimental colitis. American J Gastaroenterology 2008;103(S):187 [Abstract]
96. Available from: http://clinicaltrials.gov/ct2/results?term=linaclotide.
97. Available from: http://www.synergybio.net/sp304.htm.
98. Suzuki M, Morita T, Iwamoto T. Diversity of Cl(-) channels. Cell Mol Life Sci 2006;63(1):12-24
99. Blikslager AT, Moeser AJ, Gookin JL, et al. Restoration of barrier function in injured intestinal mucosa. Physiol Rev 2007;87(2):545-564
100. Moeser AJ, Nighot PK, Engelke KJ, et al. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol 2007;292(2):G647-56
101. Moeser AJ, Nighot PK, Roerig B, et al. Comparison of the chloride channel activator lubiprostone and the oral laxative Polyethylene Glycol 3350 on mucosal barrier repair in ischemic-injured porcine intestine. World J Gastroenterol 2008;14(39):6012-6017
102. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007;25(11):1351-1361
103. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008;103(1):170-177
104. Johanson JF, Drossman DA, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27(8):685-696
105. Chey WD, Scott C, Panas RM, Ueno R. Lubiprostone is effective and well tolerated through 48 weeks of treatment in adults with irritable bowel syndrome and constipation. Gastroenterology 2008;134(4 Suppl 1):A-215
106. Chey WD, Scott C, Panas RM, Ueno R. What symptoms drive global symptom improvement with lubiprostone in patients with irritable bowel syndrome and constipation: data from two multicenter, randomized, placebo-controlled trials. Gastroenterology 2008;134(4 Suppl 1):A-28
107. Chey WD, Panas RM, Wahle A, Ueno R. Discontinuation of lubiprostone treatment for irritable bowel syndrome with constipation is not associated with symptom increase or recurrence: results from a randomized withdrawal study. Gastroenterology 2008;134(4 Suppl 1):A-401
108. Maggi CA. The mammalian tachykinin receptors. Gen Pharmacol 1995;26(5):911-944
109. Lecci A, Capriati A, Maggi CA. Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome. Br J Pharmacol 2004;141(8):1249-1263
110. Desvignes C, Rouquier L, Souilhac J, et al. Control by tachykinin NK(2) receptors of CRF(1) receptor-mediated activation of hippocampal acetylcholine release in the rat and guinea-pig. Neuropeptides 2003;37(2):89-97
111. Available from: http://www.menarini.com/menarini/r-d/aree-terapeutiche/ development-projects/nepadutant.
112. Houghton LA, Cremonini F, Camilleri M, et al. Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol Motil 2007;19(9):732-743
113. Dukes GE, Sanger GJ, Ameen VA, et al. Lack of effect of the NK3 receptor antagonist, talnetant SB223242 on symptoms of IBS: results of 2 randomized, double-blind, placebo-controlled dose rnaging trials. Gastroenterology 2007;132(4 Suppl 2):A 60
114. Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1991;43(4):425-473
115. Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Brain Res Rev 1990;15(2):71-100
116. Tache Y, Monnikes H, Bonaz B, Rivier J. Role of CRF in stress-related alterations of gastric and colonic motor function. Ann NY Acad Sci 1993;697:233-243
117. Sagami Y, Shimada Y, Tayama J, et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004;53(7):958-964
118. Sweetser S, Camilleri M, Linker Nord SJ, et al. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am J Physiol Gastrointest Liver Physiol 2009;296(6):G1299-306
119. Available from: http://clinicaltrials.gov/ct2/results?term=GW876008.
120. Available from: http://www.who.int/foodsafety/publications/fs-management/ en/probiotics.pdf.
121. Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005;100(2):373-382
122. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005;17(5):687-696
123. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008;14(17):2650-2661
124. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101(7):1581-1590
125. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17(7):895-904
126. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007;26(3):475-486
127. Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;29(1):104-117
128. Agrawal A, Whorwell PJ. Irritable bowel syndrome: diagnosis and management. BMJ 2006;332(7536):280-283
129. Whitehead WE, Palsson OS, Levy RR, et al. Comorbidity in irritable bowel syndrome. Am J Gastroenterol 2007;102(12):2767-2776
130. Camilleri M, Chang L. Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology 2008;135(6):1877-1891
131. Kapeller J, Houghton LA, Monnikes H, et al. First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet 2008;17(19):2967-2977
132. Camilleri M, Carlson P, Zinsmeister AR, et al. Mitochondrial DNA, gastrointestinal motor and sensory functions in health and functional gastrointestinal disorders. Am J Physiol Gastrointest Liver Physiol 2009;296(3):G510-G516
133. Catterall WA, Dib-Hajj S, Meisler MH, Pietrobon D. Inherited neuronal ion channelopathies: new windows on complex neurological diseases. J Neurosci 2008;28(46):11768-11777
134. Cole JA, Rothman KJ, Cabral HJ, et al. Migraine, fibromyalgia, and depression among people with IBS: a prevalence study. BMC Gastroenterol 2006;6:26
135. Saito YA, Strege PR, Tester DJ, et al. Sodium channel mutation in irritable bowel syndrome: evidence for an ion channelopathy. Am J Physiol Gastrointest Liver Physiol 2009;296(2):G211-8
136. Akbar A, Yiangou Y, Facer P, et al. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008;57(7):923-929
137. Chan CL, Facer P, Davis JB, et al. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet 2003;361(9355):385-391
138. Camilleri M, Carlson P, McKinzie S, et al. Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am J Physiol Gastrointest Liver Physiol 2008;294(1):G13-9
139. Hornby PJ, Prouty SM. Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol 2004;141(8):1335-1345
140. Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett 2008;29(2):192-200
141. Bueno L. Protease activated receptor 2: a new target for IBS treatment. Eur Rev Med Pharmacol Sci 2008;12(Suppl 1):95-102
142. Vergnolle N. Modulation of visceral pain and inflammation by protease-activated receptors. Br J Pharmacol 2004;141(8):1264-1274
143. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108(1):65-72